- The Spanish pharmaceutical company Esteve has inaugurated its newplant in Naucalpan de Juarez, Mexico, where it plans to produce active ingredients for the pharmaceutical industry. The new plant was established through the acquisition by Esteve of local company Sintenovo. Representing the Spanish firm, Josep Esteve said at the inauguration ceremony that the group is particularly interested in establishing itself in the North American Free Trade Association region, which covers Mexico, Canada and the USA.
Esteve has invested 2 billion pesetas ($13.89 million) in Sintenovo, which has 65 staff. The firm produces anti-inflammatory products and in 1996 achieved turnover of 1.1 billion pesetas and undisclosed profits, reports the Spanish newspaper Cinco Dias.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze